August 15, 2016 BY Valentina Kirilova

QIAGEN returns $250 million to shareholders via synthetic share repurchase proposal

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA), the Dutch provider of sample and assay technologies for molecular diagnostics, has announced plans to return approximately $250 million to shareholders through a synthetic share repurchase proposal that combines a direct capital repayment with a reverse stock split. These actions, which will lead to an adjustment in…

Read more